Explore our portfolio of active, recruiting, and completed clinical trials across oncology, neurology, rare diseases, and infectious diseases. Powered by Zenth AI for faster recruitment and better outcomes.
A randomized, double-blind, placebo-controlled Phase 3 study evaluating Zenth-Alpha monotherapy versus standard of care in treatment-naïve patients with EGFR-mutated NSCLC. Primary endpoint: Progression-Free Survival (PFS).
An open-label, Phase 2 study assessing the safety and cognitive efficacy of Zenth-NeuroX, a monoclonal antibody targeting amyloid-beta plaques, in patients with mild cognitive impairment due to early-onset Alzheimer's.
A Phase 3, single-arm study evaluating the intravenous administration of ZHS-GT12, an AAV9-based gene therapy, in infants with SMA1. Primary outcome: Achievement of motor milestones at 18 months.
Completed Phase 3 study demonstrating significant improvement in Overall Survival with Zenth-CytoK maintenance compared to placebo in patients with resected Stage III melanoma. Data led to accelerated regulatory approval.
Upcoming Phase 2 study evaluating autologous cardiac stem cell therapy in patients with HFrEF. Protocol currently under IRB review. Anticipated start date: Q2 2025.
Zenth Health Sciences prioritizes research areas with significant unmet medical needs, leveraging our conglomerate's AI and advanced manufacturing capabilities.
Novel targeted therapies, immunotherapies, and combination approaches for solid and hematologic malignancies.
Breakthroughs in neurodegenerative diseases, neuromuscular disorders, and CNS therapeutics using Zenth-AI drug discovery.
Gene therapies and orphan drugs for ultra-rare conditions, powered by our specialized Aevum Rare Disease Unit.
Rapid-response vaccine platforms and next-generation antimicrobials, integrated with Zenth Biosafety facilities.
Regenerative cardiology, metabolic interventions, and novel anticoagulants for cardiovascular health.
Biologic and small molecule therapies for autoimmune disorders, focusing on remission and safety.
Whether you're an investigative site, biotech partner, or patient advocacy group, discover how our integrated clinical operations can accelerate your research.